<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of liver biochemical tests
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of liver biochemical tests
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of liver biochemical tests
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence S Friedman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of blood tests are available that reflect the condition of the liver [
         <a href="#rid1">
          1-3
         </a>
         ]. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests were previously referred to as "liver function tests." However, this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         This topic will provide an overview of liver biochemical tests. The approach to patients with abnormal liver tests is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests", section on 'Common liver biochemical and function tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1058899940">
         <span class="h1">
          CLINICAL APPLICATION OF LIVER BIOCHEMICAL TESTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver biochemical tests provide a noninvasive method to screen for the presence of liver disease, measure the efficacy of treatments for liver disease (eg, immunosuppressant agents for autoimmune hepatitis), monitor the progression of a disease (eg, viral or alcohol-associated hepatitis) and can reflect the severity of liver disease, particularly in patients who have cirrhosis. As an example, the Child-Turcotte-Pugh score (Child-Pugh class), which incorporates the prothrombin time and serum bilirubin and albumin concentrations, can predict survival  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Liver biochemical tests can be categorized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests that detect injury to hepatocytes –
         </strong>
         Hepatic enzymes, such as the aminotransferases, are normally intracellular and released into circulation when hepatocytes are injured. Other hepatic enzymes including lactate dehydrogenase, glutamate dehydrogenase, isocitrate dehydrogenase, and
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         dehydrogenase are also measures of liver injury but are less sensitive measures as compared with aminotransferases. (See
         <a class="local">
          'Liver tests that reflect generalized damage to hepatocytes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests of the liver's capacity to transport organic anions and metabolize drugs –
         </strong>
         The best studied tests that measure the liver's ability to clear endogenous or exogenous substances from the circulation include serum measurements of bilirubin, bile acids, caffeine, and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         metabolites, a variety of breath tests, and clearance tests such as bromsulphalein and
         <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">
          indocyanine green
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests of the liver's biosynthetic capacity
         </strong>
         <strong>
          –
         </strong>
         Serum albumin and the prothrombin time (which requires the presence of clotting factors produced in the liver) are the most commonly performed tests to assess the biosynthetic capacity of the liver. Other tests that reflect the liver's biosynthetic capacity include serum concentrations of lipoproteins, ceruloplasmin, ferritin, and alpha-1 antitrypsin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests that detect chronic inflammation in the liver, altered immunoregulation, or viral hepatitis
         </strong>
         <strong>
          –
         </strong>
         These tests include the immunoglobulins, hepatitis serologies, and specific autoantibodies. Most of these substances are proteins made by B lymphocytes, not by hepatocytes. However, some are quite specific for certain liver diseases, such as antimitochondrial antibodies in primary biliary cholangitis. (See
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The pattern of abnormalities of these biochemical tests is more accurate than any of the individual tests. Elevation of serum aminotransferases indicates hepatocellular injury (which may be accompanied by elevation of the serum total bilirubin), while elevation of the alkaline phosphatase and serum total bilirubin indicates cholestasis. Recognition of these patterns can prompt appropriate additional testing to determine the etiology. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests", section on 'Common liver biochemical and function tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H443970682">
         <span class="h1">
          LIVER TESTS THAT REFLECT GENERALIZED DAMAGE TO HEPATOCYTES
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Serum aminotransferases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum aminotransferases (formerly called transaminases) are sensitive indicators of liver cell injury [
         <a href="#rid6">
          6-8
         </a>
         ]. The most commonly measured are alanine aminotransferase (ALT; serum glutamic-pyruvic transaminase [SGPT]) and aspartate aminotransferase (AST; serum glutamic-oxaloacetic transaminase [SGOT]). These enzymes catalyze the transfer of the alpha-amino groups of alanine and aspartate, respectively, to the alpha-keto group of ketoglutarate, which results in the formation of pyruvate and oxaloacetate.
        </p>
        <p class="headingAnchor" id="H2578394766">
         <span class="h3">
          Source of AST and ALT
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALT is present in highest concentration in the liver [
         <a href="#rid9">
          9,10
         </a>
         ]. AST is found, in decreasing order of concentration, in the liver, cardiac muscle, skeletal muscle, kidneys, brain, pancreas, spleen, lungs, leukocytes, and erythrocytes, and is less specific than ALT for liver disease [
         <a href="#rid3">
          3
         </a>
         ]. The source of these enzymes in serum has never been clearly established, although they probably originate in tissues rich in ALT and AST.
        </p>
        <p>
         The location of the aminotransferases within cells is variable. ALT is found exclusively in the cytosol, whereas AST occurs in the cytosol and mitochondria [
         <a href="#rid10">
          10
         </a>
         ]. The cytosolic and mitochondrial forms of AST are immunologically distinct isoenzymes, which can be distinguished by several laboratory techniques [
         <a href="#rid11">
          11
         </a>
         ]. Approximately 80 percent of AST activity in human liver is derived from the mitochondrial isoenzyme [
         <a href="#rid10">
          10
         </a>
         ]. In contrast, most of the circulating AST activity in healthy people is derived from the cytosolic isoenzyme [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Isoenzyme analysis of serum ALT or AST is not routinely performed as neither have tissue-specific isoenzymes, except in acute myocardial infarction (MI) and chronic (but not acute) alcohol-associated liver disease, both of which are associated with an increase in mitochondrial AST [
         <a href="#rid12">
          12,13
         </a>
         ]. Large increases in mitochondrial AST occur in serum after extensive tissue necrosis, and assays of mitochondrial AST were previously used for the diagnosis of acute myocardial infarction [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86.html" rel="external">
          "Troponin testing: Clinical use"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H45648899">
         <span class="h3">
          Measurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Of the numerous methods developed for measuring ALT and AST activity in serum, the most specific method involves the indirect measurement of lactate and malate (derived from the formation of pyruvate and oxaloacetate, respectively, in the aminotransferase reactions) [
         <a href="#rid12">
          12
         </a>
         ]. During this reaction, the reduced form of nicotinamide-adenine dinucleotide (NADH; the cofactor in the reaction) is oxidized to NAD. Because NADH, but not NAD, absorbs light at 340 nm, the event can be followed spectrophotometrically by the loss of absorptivity at 340 nm.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Interpreting the results
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normal range
         </strong>
         <strong>
          –
         </strong>
         ALT levels are normally higher in males than females and vary directly with body mass index and, to a lesser degree, with serum lipid levels and age [
         <a href="#rid14">
          14,15
         </a>
         ]. In the absence of identifiable risk factors for liver disease, the normal serum ALT level ranges from 29 to 33 international units/L for males and 19 to 25 international units/L for females [
         <a href="#rid1">
          1
         </a>
         ]. In females, ALT levels fluctuate during the normal menstrual cycle, possibly mediated by progesterone, with peak levels in the mid-follicular phase and trough levels in the late luteal phase [
         <a href="#rid16">
          16
         </a>
         ]. Levels decline with age and in frail older adults and are inversely associated with loss of independence and death [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests", section on 'Common liver biochemical and function tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The activity of the serum aminotransferases reflects the rate at which they enter and are cleared from the circulation. An elevation in serum ALT and AST is usually related to damage or destruction of tissues rich in the aminotransferases or to changes in cell membrane permeability that permit leakage into the circulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clearance of the serum aminotransferases is similar to that of other proteins and involves catabolism by the reticuloendothelial system; AST is cleared more rapidly than ALT [
         <a href="#rid18">
          18
         </a>
         ]. The major site of AST clearance is the hepatic sinusoidal cell [
         <a href="#rid19">
          19
         </a>
         ]. It is unlikely that biliary or urinary excretion has a significant role since the enzymes are virtually undetectable in the urine and present in only very small amounts in bile [
         <a href="#rid18">
          18,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes of elevated AST and ALT
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver disease
         </strong>
         <strong>
          –
         </strong>
         Serum aminotransferases are elevated in most liver diseases and in disorders that involve the liver (such as various infections, metabolic dysfunction-associated steatotic (fatty) liver disease [MASLD], acute and chronic heart failure, and metastatic carcinoma). Elevations up to eight times the upper limit of normal are nonspecific and may be found in any of the above disorders. The highest elevations occur in disorders associated with extensive hepatocellular injury, such as acute viral hepatitis, ischemic hepatitis (hypoxic hepatitis, shock liver), acute drug- or toxin-induced liver injury (eg,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         toxicity), and certain biliary pathologies [
         <a href="#rid21">
          21
         </a>
         ]. The evaluation of the serum aminotransferases in various clinical settings, including use of the AST/ALT ratio, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The extent of liver cell necrosis correlates poorly with the magnitude of serum aminotransferase elevation; in addition, the absolute elevation in serum aminotransferases is of little prognostic value since the liver can recover from most forms of acute injury. There is, however, one pattern that is important to recognize: a rapid decrease in plasma AST and ALT levels, together with a rise in the plasma bilirubin concentration and prolongation of the prothrombin time, is indicative of a poor prognosis in patients with acute liver failure. Although a rapid decrease in serum aminotransferases is usually a sign of recovery from disease, it may also reflect the massive destruction of viable hepatocytes in patients with acute liver failure, signaling a poor prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In older adults, elevation of the serum ALT level (and gamma glutamyl transpeptidase level) may be associated with all-cause and cardiovascular mortality [
         <a href="#rid22">
          22
         </a>
         ], and elevation of the serum AST level and of the AST/ALT ratio may be associated with all-cause and liver-related mortality [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other conditions associated with elevation
         </strong>
         <strong>
          –
         </strong>
         The serum aminotransferases may be falsely elevated or decreased under certain circumstances. Drugs such as
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         may produce falsely elevated aminotransferase [
         <a href="#rid25">
          25
         </a>
         ]. In contrast, falsely low serum AST (but not ALT) is seen in persons with renal failure or those taking
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ]. In persons with renal failure, serum AST activity increases significantly after hemodialysis, indicating removal of an inhibitor, which does not appear to be urea [
         <a href="#rid26">
          26
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1895.html" rel="external">
          "Serum enzymes in patients with kidney failure"
         </a>
         ). Subnormal values of serum ALT have been described in patients with Crohn disease, the reason for which is unclear [
         <a href="#rid27">
          27
         </a>
         ]. Consumption of coffee and especially caffeine may lower serum ALT and AST levels by mechanisms that are incompletely understood [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Serum concentrations of other hepatic enzymes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of other hepatic enzymes have been measured but none is as useful as the aminotransferases for the diagnosis of hepatic disease.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Lactate dehydrogenase
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lactate dehydrogenase (LDH) is a cytoplasmic enzyme present in tissues throughout the body  (
         <a class="graphic graphic_table graphicRef98392" href="/z/d/graphic/98392.html" rel="external">
          table 2
         </a>
         ). Five isoenzyme forms of LDH are present in serum and can be separated by various electrophoretic techniques. The slowest migrating band predominates in the liver [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         In patients with liver disease, LDH is not as sensitive as the serum aminotransferases and has poor diagnostic specificity, even when isoenzyme analysis is used. In patients with acute hepatocellular injury, a markedly elevated serum LDH level distinguishes ischemic hepatitis (ALT-to-LDH ratio less than 1.5) from viral hepatitis (ALT-to-LDH ratio greater than or equal to 1.5) with a sensitivity and specificity of 94 and 84 percent, respectively [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         LDH is nonspecifically elevated in many other disorders  (
         <a class="graphic graphic_table graphicRef98392" href="/z/d/graphic/98392.html" rel="external">
          table 2
         </a>
         ).
         <span class="utd-adt-cnt utd-adt-labi">
          (Related Lab Interpretation Monograph(s):
          <a class="narrative narrative_labi" href="/contents/high-lactic-dehydrogenase-in-adults?topicRef=3573&amp;source=see_link">
           "High lactic dehydrogenase in adults"
          </a>
          .)
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Glutamate dehydrogenase
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of serum glutamate dehydrogenase (GHD) is seldom performed. GDH is a mitochondrial enzyme found primarily in the liver, heart, muscle, and kidneys [
         <a href="#rid33">
          33
         </a>
         ]. In the liver, it is present in highest concentration in centrilobular hepatocytes [
         <a href="#rid34">
          34
         </a>
         ]. GDH is a promising biomarker for drug-induced liver injury [
         <a href="#rid35">
          35
         </a>
         ]. Serum GDH has also been evaluated as a specific marker for liver disorders, such as alcohol-associated hepatitis, that primarily affect centrilobular hepatocytes [
         <a href="#rid36">
          36
         </a>
         ]. Although an initial report suggested that GDH may be a sensitive and relatively specific marker for alcohol-associated hepatitis, this observation has not been confirmed by others [
         <a href="#rid6">
          6,37
         </a>
         ].
        </p>
        <p>
         The presence of GDH in the stool is used in the diagnosis of
         <em>
          Clostridiosis difficile
         </em>
         infection [
         <a href="#rid38">
          38
         </a>
         ]. GDH antigen is an essential enzyme produced constitutively by all
         <em>
          C. difficile
         </em>
         isolates. Testing for GDH antigen is useful as an initial screening step in a multistep approach to the evaluation of a patient with suspected
         <em>
          C. difficile
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Clinical features and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Isocitrate dehydrogenase
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of isocitrate dehydrogenase is not performed clinically as it offers no diagnostic advantage over the serum aminotransferases. Isocitrate dehydrogenase, a cytoplasmic enzyme, is found in the liver, heart, kidneys, and skeletal muscle [
         <a href="#rid39">
          39
         </a>
         ]. Its activity in serum parallels that of the serum aminotransferases in acute and chronic hepatitis, but it is less sensitive [
         <a href="#rid40">
          40,41
         </a>
         ]. Although elevations in serum isocitrate dehydrogenase are relatively specific for liver disorders, increased concentrations have been reported in disseminated malignancy without detectable hepatic involvement [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Sorbitol dehydrogenase
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          Sorbitol
         </a>
         dehydrogenase is a cytoplasmic enzyme found predominantly in the liver with relatively low concentrations in the prostate gland and kidneys [
         <a href="#rid39">
          39
         </a>
         ]. Its activity in serum parallels that of the aminotransferases in hepatobiliary disorders. However, it appears to be less sensitive, and values may be normal in cirrhosis and other chronic liver disorders. Its instability in serum further limits its diagnostic utility [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3743354395">
         <span class="h1">
          LIVER TESTS THAT REFLECT CHOLESTASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevation of serum total bilirubin and alkaline phosphatase indicates cholestasis. Enzymatic measures of cholestasis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3612.html" rel="external">
          "Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1178542470">
         <span class="h2">
          Bilirubin
         </span>
        </p>
        <p class="headingAnchor" id="H2020743129">
         <span class="h3">
          Synthesis and metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilirubin is the catabolic product of heme metabolism, which is formed by the breakdown of heme present in hemoglobin, myoglobin, cytochromes, catalase, peroxidase, and tryptophan pyrrolase  (
         <a class="graphic graphic_figure graphicRef65197" href="/z/d/graphic/65197.html" rel="external">
          figure 1
         </a>
         ). Eighty percent of the daily bilirubin production (250 to 400 mg) is derived from hemoglobin; the remaining 20 percent is contributed by other heme proteins and a small pool of free heme that turns over rapidly. Some of the bilirubin produced is then conjugated in the liver  (
         <a class="graphic graphic_figure graphicRef52393" href="/z/d/graphic/52393.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3622.html" rel="external">
          "Bilirubin metabolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3101440659">
         <span class="h3">
          Measurement of serum bilirubin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several laboratory techniques have been developed for measuring the serum bilirubin concentration [
         <a href="#rid44">
          44,45
         </a>
         ]. The specific technique used has implications for the interpretation of serum values.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          van den Bergh method
         </strong>
         <strong>
          –
         </strong>
         The terms "direct-" and "indirect-reacting" bilirubin were based upon laboratory techniques developed at the beginning of the 20th century that are still used in many clinical laboratories (van den Bergh method) [
         <a href="#rid46">
          46
         </a>
         ]. Direct and indirect bilirubin reflect the concentrations of conjugated and unconjugated bilirubin, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The technique involves the reaction of bilirubin with a diazo compound (diazotized sulfanilic acid), which creates two relatively stable dipyrryl azopigments. These fractions can be detected spectrophotometrically (their maximal absorption occurs at 540 nm). The indirect and direct fractions can be distinguished based upon their rate of production in the absence or presence of alcohol. The fraction produced within one minute in the absence of alcohol represents the concentration of direct bilirubin; the total serum bilirubin is that amount that reacts in 30 minutes after the addition of alcohol; and the indirect fraction is the difference between the total and the direct bilirubin. The fast reaction of direct (conjugated bilirubin) is due to the absence of internal hydrogen bonding and the fact that it is water soluble.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Total serum bilirubin concentrations using this technique are between 0.2 and 0.9 mg/dL (2 to 15.4 micromol/L) in 95 percent of the general population, and below 1 mg/dL (18 micromol/L) in 99 percent [
         <a href="#rid46">
          46,47
         </a>
         ]. Direct bilirubin represents up to 30 percent, or 0.3 mg/dL (5.1 micromol/L), of the total bilirubin concentration [
         <a href="#rid46">
          46,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advances in laboratory methodology have demonstrated that the diazo method may not accurately reflect the concentration of conjugated and unconjugated bilirubin. Direct bilirubin overestimates the conjugated bilirubin concentration because a fraction of unconjugated bilirubin (about 10 to 15 percent) also gives a direct reaction using the van den Bergh method. There are several other potential sources of error. Endogenous substances, such as plasma lipids, and drugs, such as
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         , interfere with the diazo reaction, and can produce unreliable results. Fortunately, these interactions are only significant when the bilirubin concentration is normal or slightly elevated [
         <a href="#rid49">
          49,50
         </a>
         ]. Bilirubin complexed to albumin (delta bilirubin) also may give a direct reaction [
         <a href="#rid51">
          51,52
         </a>
         ]. The observation that jaundiced patients with hepatobiliary diseases have lower serum bilirubin concentrations measured by non-diazo- than diazo-based methods suggests that there are additional diazo-positive compounds distinct from bilirubin in their circulation [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A method based on the oxidation of bilirubin to biliverdin using vanadic acid as an oxidizing agent is simpler and faster than the diazo method and may be used for samples containing interfering substances [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alkaline methanolysis
         </strong>
         <strong>
          –
         </strong>
         A more accurate and sensitive quantification of bilirubin requires chromatographic analysis, such as high-performance liquid chromatography (HPLC) and reflectance fluorometry. One such method involves alkaline methanolysis of bilirubin followed by chloroform extraction of the bilirubin methyl esters. Separation of these esters is performed using HPLC and spectrophotometry [
         <a href="#rid49">
          49,50
         </a>
         ]. Using HPLC, conjugated bilirubin accounts for approximately 4 percent of the total serum bilirubin [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other HPLC-based methods are also available that do not require alkaline methanolysis, although globulins and other high-molecular weight proteins must be precipitated from serum before chromatography [
         <a href="#rid55">
          55,56
         </a>
         ]. In general, HPLC-based methods are too complex for routine testing [
         <a href="#rid45">
          45
         </a>
         ]. Highly accurate methods for direct analysis of free bilirubin in serum combine HPLC and thermal lens spectometry or diode array detection [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other methods
         </strong>
         <strong>
          –
         </strong>
         Several other methods that use dry reagent chemistry have been reported. One method, which is used in many clinical chemistry laboratories, is based upon photographic film technology [
         <a href="#rid55">
          55
         </a>
         ]. It can be automated and appears able to measure conjugated and unconjugated bilirubin accurately. This technique also has the advantage of being able to detect delta bilirubin, the fraction conjugated to albumin. A method using reagent-free visible-near-infrared spectroscopy has been proposed for rapid screening of large populations [
         <a href="#rid58">
          58
         </a>
         ]. Other methods under study involve luminescence and Raman spectroscopy, molecular imprinting, and piezoelectric techniques and use of conjugated nanoparticles as a fluorescence probe [
         <a href="#rid44">
          44,59,60
         </a>
         ]. Point-of-care transcutaneous techniques using miniaturized analytic devices are under study [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3068284347">
         <span class="h3">
          Clinical interpretation
         </span>
        </p>
        <p class="headingAnchor" id="H1214470052">
         <span class="h4">
          Normal range
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mean total bilirubin levels are higher in males than in females and higher in White and Hispanic populations compared with Black populations. In a steady state, the serum bilirubin concentration usually reflects the intensity of jaundice and the amount of bilirubin pigment in the body. However, several factors can influence the relationship between serum bilirubin and the total body bilirubin content. The serum bilirubin concentration may be lowered transiently by salicylates, sulfonamides, or free fatty acids, which displace bilirubin from its attachment to plasma albumin, thereby enhancing transfer of the pigment into tissues [
         <a href="#rid61">
          61
         </a>
         ]. In contrast, an increase in the serum albumin concentration (eg, due to volume contraction) may induce a temporary shift of bilirubin from tissue sites into the circulation [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Virtually 100 percent of the serum bilirubin in healthy people, including those with Gilbert syndrome, is unconjugated. Conjugated hyperbilirubinemia occurs only in hepatobiliary diseases.
        </p>
        <p class="headingAnchor" id="H4198479993">
         <span class="h4">
          Total serum bilirubin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The bilirubin normally present in serum reflects a balance between production and clearance. Thus, elevated serum bilirubin concentrations can be due to three causes, which can sometimes coexist:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overproduction of bilirubin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired uptake, conjugation, or excretion of bilirubin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Backward leakage from damaged hepatocytes or bile ducts
        </p>
        <p>
        </p>
        <p>
         Total serum bilirubin is
         <strong>
          not
         </strong>
         a sensitive indicator of hepatic dysfunction. Concentrations of serum bilirubin may be normal despite moderate to severe hepatic parenchymal injury or a partially or transiently obstructed bile duct. This lack of sensitivity can be explained in part by the reserve capacity of the human liver to remove bilirubin [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
         Serum bilirubin levels and duration of elevation may be of utility in determining disease prognosis is some conditions. The higher the serum bilirubin concentration in viral hepatitis, the greater the histologic evidence of hepatocellular damage and the longer the course of the disease [
         <a href="#rid65">
          65
         </a>
         ]. Similarly a serum bilirubin concentration higher than 5 mg/dL (85.5 micromol/L) is associated with a poor prognosis in alcohol-associated hepatitis [
         <a href="#rid66">
          66,67
         </a>
         ]. A rising bilirubin concentration suggests a poor prognosis in patients with primary biliary cholangitis [
         <a href="#rid68">
          68
         </a>
         ]. However, the correlation of serum bilirubin concentration with disease outcome does not always hold true. As an example, patients may die of acute liver failure with only modest elevations of the serum bilirubin. Furthermore, conditions associated with excess bilirubin production (such as hemolysis) or decreased clearance (such as renal insufficiency) can result in hyperbilirubinemia out of proportion to the degree of hepatic dysfunction.
        </p>
        <p>
         The serum total bilirubin concentration is seldom of value in specifying the cause of jaundice in individual patients because values among the various causes of jaundice overlap considerably [
         <a href="#rid69">
          69
         </a>
         ]. An approach to patients who present with hyperbilirubinemia is presented separately (see
         <a class="medical medical_review" href="/z/d/html/3620.html" rel="external">
          "Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia"
         </a>
         ).
        </p>
        <p>
         In the general population, serum bilirubin levels correlate with the risk of symptomatic gallstone disease [
         <a href="#rid70">
          70
         </a>
         ] and inversely with the risk of stroke, respiratory disease, cardiovascular disease, peripheral artery disease, and mortality, presumably because bilirubin has antioxidant properties and perhaps because it is a signaling molecule [
         <a href="#rid71">
          71
         </a>
         ]. However, the serum bilirubin level has been reported to correlate with mortality in patients with acute myocardial infarction complicated by heart failure [
         <a href="#rid70">
          70,72-77
         </a>
         ] and in patients with chronic obstructive lung disease [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H962311711">
         <span class="h4">
          Unconjugated and conjugated bilirubin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major value of fractionating total serum bilirubin is for the detection of states characterized by unconjugated hyperbilirubinemia  (
         <a class="graphic graphic_table graphicRef55607" href="/z/d/graphic/55607.html" rel="external">
          table 3
         </a>
         ). Elevated levels of unconjugated bilirubin usually result from overproduction or impaired uptake or conjugation of bilirubin. These diagnoses should be considered when the serum indirect bilirubin concentration is greater than 1.2 mg/dL (20.5 micromol/L) and the direct fraction constitutes less than 15 percent of the total serum bilirubin.
        </p>
        <p>
         In contrast, conjugated hyperbilirubinemia is more commonly due to decreased excretion or backward leakage (as from an obstructed biliary system) and is usually a more sensitive indicator of hepatic dysfunction. Using the diazo method, an increase in the conjugated (direct) bilirubin concentration above 0.3 mg/dL (5.1 micromol/L) or, using the more accurate techniques, a conjugated bilirubin concentration above 0.1 mg/dL (1.7 micromol/L) should raise suspicion for liver injury [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3615.html" rel="external">
          "Classification and causes of jaundice or asymptomatic hyperbilirubinemia"
         </a>
         .)
        </p>
        <p>
         Fractionation of the serum bilirubin concentration in jaundiced patients does not permit accurate distinction between parenchymal (hepatocellular) and cholestatic (obstructive) jaundice. The accurate HPLC methods for measuring serum bilirubin demonstrate that unconjugated and conjugated bilirubin are both increased in hepatobiliary disease without a consistent difference in pattern [
         <a href="#rid50">
          50
         </a>
         ]. Levels of both bilirubin monoglucuronide and diglucuronide in hepatobiliary disease are elevated, with the monoglucuronides predominating.
        </p>
        <p class="headingAnchor" id="H404580601">
         <span class="h4">
          Urine bilirubin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of bilirubin in the urine reflects direct hyperbilirubinemia and therefore underlying hepatobiliary disease. In contrast to conjugated bilirubin, unconjugated bilirubin is tightly bound to albumin; as a result, it is not filtered by the glomerulus or present in the urine.
        </p>
        <p>
         Conjugated bilirubin may be found in the urine when the total serum bilirubin concentration is normal because the renal reabsorptive capacity for conjugated bilirubin is low and the methods used can detect urinary bilirubin concentrations as low as 0.05 mg/dL (0.9 micromol/L) [
         <a href="#rid79">
          79
         </a>
         ]. Thus, bilirubinuria may be an early sign of liver disease, while the clearance of bilirubin from the urine may be an early sign of recovery, since, as noted above, delta bilirubin is protein-bound (thereby increasing its half-life in serum compared with nonbound conjugated bilirubin and preventing its filtration across the glomerulus) [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24800711">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical application of liver tests –
         </strong>
         Liver biochemical tests provide a noninvasive method to screen for the presence of liver disease, measure the efficacy of treatments for liver disease (eg, immunosuppressant agents for autoimmune hepatitis), and monitor the progression of a disease (eg, viral or alcohol-associated hepatitis) and can reflect the severity of liver disease, particularly in patients who have cirrhosis. These tests are often referred to as "liver function tests," although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease. (See
         <a class="local">
          'Clinical application of liver biochemical tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests that reflect hepatocyte damage
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serum aminotransferases
         </strong>
         <strong>
          –
         </strong>
         The serum aminotransferases (formerly called transaminases) are sensitive indicators of hepatocyte injury. The most commonly measured are alanine aminotransferase (ALT; serum glutamic-pyruvic transaminase) and aspartate aminotransferase (AST; serum glutamic-oxaloacetic transaminase). (See
         <a class="local">
          'Serum aminotransferases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Serum aminotransferases are elevated in most liver diseases and in disorders that involve the liver (such as various infections, drug toxicity metabolic dysfunction-associated steatotic (fatty) liver disease [MASLD], acute heart failure, and metastatic carcinoma). Elevations up to eight times the upper limit of normal are nonspecific and may be found in many disorders involving the liver. The highest elevations occur in disorders associated with extensive hepatocellular injury, such as acute viral hepatitis, ischemic hepatitis (hypoxic hepatitis, shock liver), and acute drug- or toxin-induced liver injury (eg,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         toxicity). (See
         <a class="local">
          'Serum aminotransferases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other tests
         </strong>
         <strong>
          –
         </strong>
         A variety of other hepatic enzymes (such as lactate dehydrogenase) have been measured, but none is as useful as the aminotransferases for the diagnosis of hepatic disease. (See
         <a class="local">
          'Serum concentrations of other hepatic enzymes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests reflecting cholestasis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Total serum bilirubin
         <strong>
          is not
         </strong>
         a sensitive indicator of hepatic dysfunction. The bilirubin normally present in serum reflects a balance between production and clearance. Thus, elevated serum bilirubin concentrations can be due to three causes, which can sometimes coexist:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Overproduction of bilirubin
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Impaired uptake, conjugation, or excretion of bilirubin
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Backward leakage from damaged hepatocytes or bile ducts
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The major value of fractionating total serum bilirubin is for the detection of states characterized by unconjugated hyperbilirubinemia  (
         <a class="graphic graphic_table graphicRef55607" href="/z/d/graphic/55607.html" rel="external">
          table 3
         </a>
         ). Elevated levels of unconjugated bilirubin usually result from overproduction or impaired uptake or conjugation of bilirubin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevation of serum total bilirubin and alkaline phosphatase indicates cholestasis. Enzymatic measures of cholestasis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3612.html" rel="external">
          "Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017; 112:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reutemann B, Gordon FD. Evaluation of the Patient with Markedly Abnormal Liver Enzymes. Clin Liver Dis 2023; 27:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith A, Baumgartner K, Cooper J, St Louis J. Liver Disease: Evaluation of Patients With Abnormal Liver Test Results. FP Essent 2021; 511:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan MK, Daher HB, Rockey DC. Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis. Am J Med Sci 2022; 363:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978; 70:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WROBLEWSKI F. The clinical significance of transaminase activities of serum. Am J Med 1959; 27:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ZIMMERMAN HJ, WEST M. SERUM ENZYME LEVELS IN THE DIAGNOSIS OF HEPATIC DISEASE. Am J Gastroenterol 1963; 40:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyde TR, Latner AL. Starch gel electrophoresis of transaminase in human tissue extracts and serum. Biochem J 1961; 82:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem 1978; 24:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MORINO Y, KAGAMIYAMA H, WADA H. IMMUNOCHEMICAL DISTINCTION BETWEEN GLUTAMIC-OXALOACETIC TRANSAMINASES FROM THE SOLUBLE AND MITOCHONDRIAL FRACTIONS OF MAMMALIAN TISSUES. J Biol Chem 1964; 239:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rej R. Measurement of aminotransferases: Part 1. Aspartate aminotransferase. Crit Rev Clin Lab Sci 1984; 21:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalpas B, Vassault A, Charpin S, et al. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology 1986; 6:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HY, Kim CW, Lee CD, et al. Can "healthy" normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010. Dig Dis Sci 2014; 59:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui MS, Sterling RK, Luketic VA, et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013; 145:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai CW, Jadhav S, Njei B, et al. Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight. Clin Gastroenterol Hepatol 2020; 18:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamazaki H, Kamitani T, Matsui T, et al. Association of low alanine aminotransferase with loss of independence or death: A 5-year population-based cohort study. J Gastroenterol Hepatol 2019; 34:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DUNN M, MARTINS J, REISSMANN KR. The disappearance rate of glutamic oxalacetic transaminase from the circulation and its distribution in the body's fluid compartments and secretions. J Lab Clin Med 1958; 51:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985; 5:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FRANKL HD, MERRITT JH. Enzyme activity in the serum and common duct bile of dogs. Am J Gastroenterol 1959; 31:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed MF, Wadhavkar N, Elfanagely Y, et al. Etiologies and Outcomes of Transaminase Elevation &gt; 1000 IU/L: A Systematic Review and Meta-Analysis. Dig Dis Sci 2023; 68:2843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahady SE, Wong G, Turner RM, et al. Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study. J Clin Gastroenterol 2017; 51:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie K, Chen CH, Tsai SP, et al. Loss of Life Expectancy by 10 Years or More From Elevated Aspartate Aminotransferase: Finding Aspartate Aminotransferase a Better Mortality Predictor for All-Cause and Liver-Related than Alanine Aminotransferase. Am J Gastroenterol 2019; 114:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu X, Liu P. Elevated AST/ALT ratio is associated with all-cause mortality in patients with stable coronary artery disease: a secondary analysis based on a retrospective cohort study. Sci Rep 2022; 12:9231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabath LD, Gerstein DA, Finland M. Serum glutamic oxalacetic transaminase. False elevations during administration of erythromycin. N Engl J Med 1968; 279:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen GA, Goffinet JA, Donabedian RK, Conn HO. Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976; 84:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vadstrup S. Subnormal alanine aminotransferase values in blood of patients with Crohn disease. Scand J Gastroenterol 2004; 39:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding J, Zhang Y. Associations of Coffee Consumption with the Circulating Level of Alanine Aminotransferase and Aspartate Aminotransferase. A Meta-Analysis of Observational Studies. J Am Coll Nutr 2021; 40:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall T, Williams J, Williams KM. Electrophoresis of serum isoenzymes and proteins following acute myocardial infarction. J Chromatogr 1991; 569:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smit MJ, Duursma AM, Bouma JM, Gruber M. Receptor-mediated endocytosis of lactate dehydrogenase M4 by liver macrophages: a mechanism for elimination of enzymes from plasma. Evidence for competition by creatine kinase MM, adenylate kinase, malate, and alcohol dehydrogenase. J Biol Chem 1987; 262:13020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994; 19:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SCHMIDT E, SCHMIDT FW. [Methods and value of determination of glutamic acid dehydrogenase activity in the serum. A contribution to the importance of examination of enzyme relations in the serum]. Klin Wochenschr 1962; 40:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guder WG, Habicht A, Kleissl J, et al. The diagnostic significance of liver cell inhomogeneity: serum enzymes in patients with central liver necrosis and the distribution of glutamate dehydrogenase in normal human liver. Z Klin Chem Klin Biochem 1975; 13:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology 2019; 69:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Waes L, Lieber CS. Glutamate dehydrogenase: a reliable marker of liver cell necrosis in the alcoholic. Br Med J 1977; 2:1508.
          </a>
         </li>
         <li class="breakAll">
          Kaplan MM, et al. Biochemical basis for serum enzyme abnormalities in alcoholic liver disease. In: Early identification of alcohol abuse, Research Monograph No. 17, Chang NC, Chan NM (Eds), NIAAA, 1985. p.186.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shetty N, Wren MW, Coen PG. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis. J Hosp Infect 2011; 77:1.
          </a>
         </li>
         <li class="breakAll">
          Rosalki, SB. Enzyme tests in disease of the liver and hepatobiliary tract. In: The principles and practice of diagnostic enzymology, Wilkinson JH (Ed), Edward Arnold, London 1973. p.303.
         </li>
         <li>
          <a class="nounderline abstract_t">
           BELL JL, SHALDON S, BARON DN. Serum isocitrate dehydrogenase in liver disease and some other conditions. Clin Sci 1962; 23:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           STERKEL RL, SPENCER JA, WOLFSON SK Jr, WILLIAMS-ASHMAN HG. Serum isocitric dehydrogenase activity with particular reference to liver disease. J Lab Clin Med 1958; 52:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WEST M, SCHWARTZ MA, COHEN J, ZIMMERMAN HJ. SERUM ENZYMES IN DISEASE. XV. GLYCOLYTIC AND OXIDATIVE ENZYMES AND TRANSAMINASES IN PATIENTS WITH CARCINOMA OF THE KIDNEY, PROSTATE AND URINARY BLADDER. Cancer 1964; 17:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol 2013; 19:6398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngashangva L, Bachu V, Goswami P. Development of new methods for determination of bilirubin. J Pharm Biomed Anal 2019; 162:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra Ruiz AR, Crespo J, López Martínez RM, et al. Measurement and clinical usefulness of bilirubin in liver disease. Adv Lab Med 2021; 2:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ZIEVE L, HILL E, HANSON M, et al. Normal and abnormal variations and clinical significance of the one-minute and total serum bilirubin determinations. J Lab Clin Med 1951; 38:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner M, Tolls RE, Hultin JV, Mellecker J. Influence of sex and age on the normal range of eleven serum constituents. Z Klin Chem Klin Biochem 1970; 8:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           TISDALE WA, KLATSKIN G, KINSELLA ED. The significance of the direct-reacting fraction of serum bilirubin in hemolytic jaundice. Am J Med 1959; 26:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanckaert N. Analysis of bilirubin and bilirubin mono- and di-conjugates. Determination of their relative amounts in biological samples. Biochem J 1980; 185:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanckaert N, Kabra PM, Farina FA, et al. Measurement of bilirubin and its monoconjugates and diconjugates in human serum by alkaline methanolysis and high-performance liquid chromatography. J Lab Clin Med 1980; 96:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanckaert N, Servaes R, Leroy P. Measurement of bilirubin-protein conjugates in serum and application to human and rat sera. J Lab Clin Med 1986; 108:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983; 309:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameri M, Schnaars H, Sibley J, Honor D. Comparison of the vanadate oxidase method with the diazo method for serum bilirubin determination in dog, monkey, and rat. J Vet Diagn Invest 2011; 23:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muraca M, Blanckaert N. Liquid-chromatographic assay and identification of mono- and diester conjugates of bilirubin in normal serum. Clin Chem 1983; 29:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Defreese JD, Wang TS. Properties and determination of serum and bilirubin. Crit Rev Clin Lab Sci 1984; 19:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauff JJ, Kasper ME, Ambrose RT. Quantitative liquid-chromatographic estimation of bilirubin species in pathological serum. Clin Chem 1983; 29:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martelanc M, Žiberna L, Passamonti S, Franko M. Direct determination of free bilirubin in serum at sub-nanomolar levels. Anal Chim Acta 2014; 809:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan H, Liao S, Pan T, et al. Rapid and simultaneous analysis of direct and indirect bilirubin indicators in serum through reagent-free visible-near-infrared spectroscopy combined with chemometrics. Spectrochim Acta A Mol Biomol Spectrosc 2020; 233:118215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chanu M, Mondal S, Zehra N et. Conjugated polymer nanoparticles as a fluorescence probe for amplified detection of human serum bilirubin. ACS Applied Polymer Materials 2022; 4:3491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quan Y, Li J, Hu M, et al. Interface synthesis of MoS2@ZnO@Ag SERS substrate for the ultrasensitive determination of bilirubin. Applied Surface Science 2022; 598:153750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmid R, Diamond I, Hammaker L, Gundersen CB. Interaction of bilirubin with albumin. Nature 1965; 206:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamond I, Schmid R. Experimental bilirubin encephalopathy. The mode of entry of bilirubin-14C into the central nervous system. J Clin Invest 1966; 45:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson HE, Wyatt BL. Experimentally induced jaundice (hyperbilirubinemia): Report of animal experimentation and of physiologic effect of jaundice in patients with atrophic arthritis. Arch Intern Med 1938; 61:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond GD, Galambos JT. Hepatic storage and excretion of bilirubin in man. Am J Gastroenterol 1971; 55:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SHERLOCK SP. Biochemical investigations in liver disease; some correlations with hepatic histology. J Pathol Bacteriol 1946; 58:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardison WG, Lee FI. Prognosis in acute liver disease of the alcoholic patient. N Engl J Med 1966; 275:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harinasuta U, Chomet B, Ishak K, Zimmerman HJ. Steatonecrosis--Mallory body type. Medicine (Baltimore) 1967; 46:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998; 28:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HOFFBAUER FW, RAMES ED, MEINERT JK. Limitations and merits of a single serum sample analysis in the differential diagnosis of jaundice. J Lab Clin Med 1949; 34:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. JAMA Intern Med 2013; 173:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vítek L. Bilirubin as a signaling molecule. Med Res Rev 2020; 40:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsfall LJ, Rait G, Walters K, et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011; 305:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh S, Cho YR, Park MK, et al. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One 2018; 13:e0193041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozeki M, Morita H, Miyamura M, et al. High serum bilirubin is associated with lower prevalence of peripheral arterial disease among cardiac patients. Clin Chim Acta 2018; 476:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapenna D, Ciofani G, Pierdomenico SD, et al. Association of serum bilirubin with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis. Clin Exp Med 2018; 18:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frikha Z, Ferreira JP, Bozec E, et al. Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). Am J Cardiol 2018; 121:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vítek L. Bilirubin as a predictor of diseases of civilization. Is it time to establish decision limits for serum bilirubin concentrations? Arch Biochem Biophys 2019; 672:108062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald DM, Kunisaki KM, Wilt TJ, Baldomero AK. Serum bilirubin and chronic obstructive pulmonary disease (COPD): a systematic review. BMC Pulm Med 2021; 21:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KLATSKIN G, BUNGARDS L. An improved test for bilirubin in urine. N Engl J Med 1953; 248:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomer JR, Berk PD, Howe RB, Berlin NI. Interpretation of plasma bilirubin levels based on studies with radioactive bilirubin. JAMA 1971; 218:216.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3573 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27995906" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29122851" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Guidelines on the management of abnormal liver blood tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36400459" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evaluation of the Patient with Markedly Abnormal Liver Enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34855337" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Liver Disease: Evaluation of Patients With Abnormal Liver Test Results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34619146" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/696683" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Serum enzyme tests in diseases of the liver and biliary tree.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13846130" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The clinical significance of transaminase activities of serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14073990" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : SERUM ENZYME LEVELS IN THE DIAGNOSIS OF HEPATIC DISEASE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Starch gel electrophoresis of transaminase in human tissue extracts and serum
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/213206" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14154476" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : IMMUNOCHEMICAL DISTINCTION BETWEEN GLUTAMIC-OXALOACETIC TRANSAMINASES FROM THE SOLUBLE AND MITOCHONDRIAL FRACTIONS OF MAMMALIAN TISSUES.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6391817" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Measurement of aminotransferases: Part 1. Aspartate aminotransferase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3732996" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24705695" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Can "healthy" normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23973920" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31811951" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30761612" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association of low alanine aminotransferase with loss of independence or death: A 5-year population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13514232" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The disappearance rate of glutamic oxalacetic transaminase from the circulation and its distribution in the body's fluid compartments and secretions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3997068" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13617246" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Enzyme activity in the serum and common duct bile of dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37184617" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Etiologies and Outcomes of Transaminase Elevation &gt; 1000 IU/L: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27479143" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425154" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Loss of Life Expectancy by 10 Years or More From Elevated Aspartate Aminotransferase: Finding Aspartate Aminotransferase a Better Mortality Predictor for All-Cause and Liver-Related than Alanine Aminotransferase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35654995" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Elevated AST/ALT ratio is associated with all-cause mortality in patients with stable coronary artery disease: a secondary analysis based on a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5686481" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Serum glutamic oxalacetic transaminase. False elevations during administration of erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1259262" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15223680" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Subnormal alanine aminotransferase values in blood of patients with Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15633120" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32343195" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Associations of Coffee Consumption with the Circulating Level of Alanine Aminotransferase and Aspartate Aminotransferase. A Meta-Analysis of Observational Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1939492" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Electrophoresis of serum isoenzymes and proteins following acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2820961" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Receptor-mediated endocytosis of lactate dehydrogenase M4 by liver macrophages: a mechanism for elimination of enzymes from plasma. Evidence for competition by creatine kinase MM, adenylate kinase, malate, and alcohol dehydrogenase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7963356" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13991973" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : [Methods and value of determination of glutamic acid dehydrogenase activity in the serum. A contribution to the importance of examination of enzyme relations in the serum].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1189532" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The diagnostic significance of liver cell inhomogeneity: serum enzymes in patients with central liver necrosis and the distribution of glutamate dehydrogenase in normal human liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29357190" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/589307" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Glutamate dehydrogenase: a reliable marker of liver cell necrosis in the alcoholic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/589307" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Glutamate dehydrogenase: a reliable marker of liver cell necrosis in the alcoholic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21145132" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21145132" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13866818" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Serum isocitrate dehydrogenase in liver disease and some other conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13563993" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Serum isocitric dehydrogenase activity with particular reference to liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14136526" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : SERUM ENZYMES IN DISEASE. XV. GLYCOLYTIC AND OXIDATIVE ENZYMES AND TRANSAMINASES IN PATIENTS WITH CARCINOMA OF THE KIDNEY, PROSTATE AND URINARY BLADDER.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24151358" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : New insights in bilirubin metabolism and their clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30273817" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Development of new methods for determination of bilirubin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37362415" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Measurement and clinical usefulness of bilirubin in liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14880760" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Normal and abnormal variations and clinical significance of the one-minute and total serum bilirubin determinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5421228" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Influence of sex and age on the normal range of eleven serum constituents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13617278" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The significance of the direct-reacting fraction of serum bilirubin in hemolytic jaundice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7378044" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Analysis of bilirubin and bilirubin mono- and di-conjugates. Determination of their relative amounts in biological samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7400659" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Measurement of bilirubin and its monoconjugates and diconjugates in human serum by alkaline methanolysis and high-performance liquid chromatography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3734589" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Measurement of bilirubin-protein conjugates in serum and application to human and rat sera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6866015" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21217041" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparison of the vanadate oxidase method with the diazo method for serum bilirubin determination in dog, monkey, and rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6616822" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Liquid-chromatographic assay and identification of mono- and diester conjugates of bilirubin in normal serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6327188" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Properties and determination of serum and bilirubin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6839457" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Quantitative liquid-chromatographic estimation of bilirubin species in pathological serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24418149" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Direct determination of free bilirubin in serum at sub-nanomolar levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32151990" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Rapid and simultaneous analysis of direct and indirect bilirubin indicators in serum through reagent-free visible-near-infrared spectroscopy combined with chemometrics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Conjugated polymer nanoparticles as a fluorescence probe for amplified detection of human serum bilirubin
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Interface synthesis of MoS2@ZnO@Ag SERS substrate for the ultrasensitive determination of bilirubin
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5839057" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Interaction of bilirubin with albumin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5949114" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Experimental bilirubin encephalopathy. The mode of entry of bilirubin-14C into the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Experimentally induced jaundice (hyperbilirubinemia): Report of animal experimentation and of physiologic effect of jaundice in patients with atrophic arthritis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5580257" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hepatic storage and excretion of bilirubin in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20283090" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Biochemical investigations in liver disease; some correlations with hepatic histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5936867" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prognosis in acute liver disease of the alcoholic patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5338701" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Steatonecrosis--Mallory body type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9657093" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Optimal timing of liver transplantation for primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18148118" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Limitations and merits of a single serum sample analysis in the differential diagnosis of jaundice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23753274" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32017160" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Bilirubin as a signaling molecule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325185" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Serum bilirubin and risk of respiratory disease and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29447261" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Relationship between serum bilirubin levels and cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29155119" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : High serum bilirubin is associated with lower prevalence of peripheral arterial disease among cardiac patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28948382" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Association of serum bilirubin with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29631805" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31376369" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Bilirubin as a predictor of diseases of civilization. Is it time to establish decision limits for serum bilirubin concentrations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33472602" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Serum bilirubin and chronic obstructive pulmonary disease (COPD): a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13037027" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : An improved test for bilirubin in urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4938053" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Interpretation of plasma bilirubin levels based on studies with radioactive bilirubin.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
